share_log

Revolution Medicines Doses First Patient In Phase 1/1b Clinical Trial Of RMC-6291, Company's First Mutant-Selective RAS(ON) Inhibitor

Benzinga Real-time News ·  Sep 22, 2022 07:08
Revolution Medicines Doses First Patient In Phase 1/1b Clinical Trial Of RMC-6291, Company's First Mutant-Selective RAS(ON) Inhibitor
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment